Surgical Outcome of Ductal Adenocarcinoma of the Body and Tail of the Pancreas.
- Author:
Yoo Seok YOON
1
;
Sun Whe KIM
;
Min Gew CHOI
;
Jin Young JANG
;
Kuhn Uk LEE
;
Yong Hyun PARK
Author Information
1. Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Pancreas body & tail cancer;
Ductal carcinoma of the pancreas;
Distal pancreatectomy;
Prognosis
- MeSH:
Adenocarcinoma*;
Biopsy;
Carcinoma, Pancreatic Ductal;
Humans;
Multivariate Analysis;
Neoplasm, Residual;
Pancreas*;
Pancreatectomy;
Prognosis;
Recurrence;
Retrospective Studies;
Survival Rate
- From:Korean Journal of Hepato-Biliary-Pancreatic Surgery
2003;7(2):206-213
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The prognosis of a ductal adenocarcinoma of the body and tail of the pancreas is poor because it is usually diagnosed at an advanced stage and is rarely resectable. The aim of this study was to evaluate the clinical outcomes after a surgical resection of an adenocarcinoma of the distal pancreas. METHODS: A total of 311 patients with an adenocarcinoma of the distal pancreas were admitted between 1985 and 2001, and of these, 54 patients were surgically treated; 29 patients underwent a distal pancreatectomy (extended resection in 12 cases), 9 underwent a palliative bypass, and 16 underwent a open biopsy. The clinical outcome of the 29 patients who underwent a surgical resection for the adenocarcinoma of the distal pancreas was retrospectively analyzed. RESULTS: The resectability rate was 9.3% (29/311). In the resected cases, the cumulative 3-year survival rate was 14.9%, whereas it was 0% (p=0.013) in the non-resected cases. Moreover, a significant survival difference was found between the curatively resected cases (n=16, 28.1%) and the palliatively resected cases (n=13, 0%)(p=0.003). After the curative resection, 11 patients (68.8%) developed a recurrence. Three patients survived more than 3 years (46, 74, 56 months), of whom only one had no recurrent disease. The size of the tumor and the residual tumor were identified as independent significant prognostic factors by multivariate analysis. CONCLUSION: Only a curative resection can offer long-term survival as well as a survival benefit in patients with a ductal adenocarcinoma of the body and tail of the pancreas. Therefore, a surgical resection should be preferably performed and efforts for a curative resection should be made. However, adjuvant therapy, local and systemic, needs to be further developed because most patients develop a recurrence after the resection.
